Taking advantage of this peculiarity of neoplastic cells, we recently developed a novel monoclonal antibody (mAb), named PODO447, that targets a glycopeptide epitope of PODXL expressed on cancer cells, but is absent on normal, PODXL-expressing podocytes and vascular endothelia (15, 16). Here, PODXL is linked to cancer.